Franco Scaldaferri

Plain English
This study looked at how effective and safe it is for patients with ulcerative colitis to switch to a second medication called JAK-inhibitors after not responding well to the first one. Out of 243 patients, about 48% achieved a good response without steroids after 12 weeks, but this dropped to 28% after a year. The findings show that if patients had problems with their first medication or were using steroids, they were less likely to benefit from the switch. Who this helps: This research benefits patients with ulcerative colitis who may need to change their medication.

Plain English
This study looks at how endoscopic ultrasound (EUS) can be used to diagnose and manage inflammatory bowel diseases (IBD) like Crohn's disease and ulcerative colitis. Researchers found that EUS can accurately assess disease activity and help predict how patients will respond to treatments, focusing on details like bowel wall thickness and vascular patterns. This matters because better imaging and monitoring can lead to more personalized treatments and improved outcomes for patients with IBD. Who this helps: Patients with inflammatory bowel diseases.

Plain English
This study looked at how satisfied patients with inflammatory bowel disease (IBD) in Italy were with telemedicine visits. Out of 705 patients, those reported high satisfaction with an average score of around 57.5 out of 70, especially when technology was easy to use and they had regular contact with their healthcare team. The findings highlight the importance of creating user-friendly telehealth services and providing support to ensure all patients can benefit from remote care. Who this helps: This helps patients with IBD who rely on telemedicine for their healthcare.

Plain English
This study looked at how depression, anxiety, and stress affect the ability of people with inflammatory bowel disease (IBD), like Crohn's disease and ulcerative colitis, to take care of themselves. It found that psychological issues lead to poorer self-care, making it harder for patients to stick to their treatment plans—especially younger patients who tend to struggle more with anxiety. Addressing mental health alongside physical treatment can significantly improve patients' overall health and how well they manage their condition. Who this helps: This helps patients with inflammatory bowel disease and their healthcare providers.

Plain English
This study looked at how fecal microbiota transplantation (FMT) from psychiatric patients to mice is being done in research. The review found that out of 31 studies, none followed the same procedure for FMT, which means the methods vary widely and can affect results. Standardizing these approaches is important for ensuring that research on how our gut bacteria influence mental health is reliable and can lead to better understanding and treatments. Who this helps: This benefits researchers and ultimately patients with psychiatric disorders.

Plain English
This study focused on creating and testing a new tool called the IBD Frailty Score, designed to assess frailty in patients with inflammatory bowel diseases like Crohn's disease and ulcerative colitis. Researchers found that the score, which can be completed in about two minutes, effectively identified frail patients and distinguished them from those who were fit, with a clear cut-off score of 4. Key factors that predicted frailty included older age, multiple medications, previous extraintestinal issues, and higher disease activity, making this tool valuable for improving patient care. Who this helps: This helps patients with inflammatory bowel diseases and their doctors by providing a reliable way to assess their health and care needs.

Plain English
This study explored how to better diagnose diabetic neuropathy by analyzing blood components from patients with type 1 diabetes. Researchers examined blood samples from 72 patients, finding that those with diabetic sensorimotor peripheral neuropathy had different blood markers compared to those without, specifically noting a strong indicator found in their plasma extracellular vesicles. This finding matters because it could lead to a quicker and more accurate way to identify patients needing intervention to manage their condition. Who this helps: Patients with type 1 diabetes experiencing neuropathic complications.

Plain English
This study focused on the effectiveness and safety of the medication Risankizumab for patients with Crohn's disease. Researchers looked at 520 patients and found that 60.8% were symptom-free after 12 weeks, and by 52 weeks, 65.6% remained free of steroid use, with 37.5% showing improvement in their intestinal condition. These findings show that Risankizumab provides significant relief for patients who have had trouble with other treatments. Who this helps: This helps patients with Crohn's disease, particularly those who haven't responded well to other medications.

Plain English
Researchers studied a type of DNA found outside of chromosomes, called extrachromosomal circular DNA (eccDNA), in patients with inflammatory bowel disease (IBD). They discovered that IBD patients had much higher levels of eccDNA compared to healthy individuals, especially those with active ulcerative colitis, who showed even more significant increases (specific numbers weren’t provided). This finding is important because it could lead to new ways to identify IBD types and monitor disease activity, potentially improving patient care and treatment outcomes. Who this helps: This helps patients with inflammatory bowel disease and their doctors.

Plain English
This study focused on how different scoring systems can predict whether Crohn's disease will return after surgery. Researchers looked at over 170 patients and found that the Rutgeerts score was fairly effective, accurately predicting a clinical recurrence in 83% of cases but was less specific (57%). The study suggests that two newer scoring systems, the POCER index and the UEDA score, may provide better insights into the risk of disease return, particularly for inflammation at the surgical site. Who this helps: This research benefits patients with Crohn's disease by improving the prediction of disease recurrence after surgery, enabling better disease management.

Plain English
This study examined how common gut-brain disorders are in children with inactive inflammatory bowel disease (IBD) compared to healthy children. It found that 41.5% of the children with IBD reported these disorders, compared to 28% of healthy kids, with functional dyspepsia being notably more common in the IBD group. Understanding these connections and the influence of psychological factors can help improve the care of children with IBD who still experience symptoms, emphasizing the importance of mental health and nutrition in their treatment. Who this helps: Patients with inflammatory bowel disease and their doctors.

Plain English
The study focused on bowel urgency, a sudden need to use the bathroom that significantly affects people with inflammatory bowel disease (IBD). Researchers found that this symptom has various aspects, including fear of accidents and anxiety about having to rush to the bathroom, which can lead to greater emotional distress and less social interaction. Assessing bowel urgency is important for improving patient care, and creating a comprehensive way to measure it could help better address this issue in patients with IBD. Who this helps: This helps patients with inflammatory bowel disease and their doctors.

Plain English
This study looked at a specific pathway in the immune system called the IL-33/ST2 axis and its role in helping heal the gut lining in patients with inflammatory bowel disease (IBD), which includes conditions like Ulcerative Colitis and Crohn's disease. Researchers found that targeting this pathway can help improve gut health and support better treatment outcomes, as it is linked to both inflammation and healing. Understanding and modifying this axis could lead to new therapies that are more effective for managing IBD. Who this helps: Patients with inflammatory bowel disease.

Plain English
This research paper looks at how fecal microbiota transplantation (FMT) can be used in mice to study diseases like inflammatory bowel disease (IBD) and short bowel syndrome (SBS). The findings show that FMT can help restore gut health and improve immune function in IBD models, specifically by enhancing beneficial bacteria and restoring gut protection. For SBS, the study highlights challenges in applying FMT due to changes in the intestine but suggests new methods for better results. Who this helps: This helps patients with gastrointestinal diseases and their doctors.

Plain English
This study looked at how heart failure (HF) affects both the heart and the gut, highlighting that problems in the gut can worsen heart conditions. Researchers found that new heart failure treatments, specifically SGLT2 inhibitors and sacubitril/valsartan, not only improve heart health but also might positively influence gut health and the bacteria living there. This matters because it could lead to better, personalized treatments for patients with heart failure. Who this helps: Patients with heart failure.

Plain English
This research looked at how the bacteria in our gut can affect inflammatory bowel diseases (IBDs) like ulcerative colitis and Crohn's disease. Researchers found that while traditional treatments for IBD are limited, new therapies that change the gut microbiota—like fecal transplants and advanced probiotics—can improve patients' quality of life. This is significant because it opens up new possibilities for treating these chronic conditions. Who this helps: Patients with inflammatory bowel diseases.

Plain English
This research paper looks at how gut bacteria affect inflammatory bowel disease (IBD), which includes conditions like Crohn's disease and ulcerative colitis. Researchers found that understanding and managing gut microbiota can significantly improve diagnostic methods and treatments for IBD. For example, personalized therapies based on a patient’s specific gut bacteria profile are becoming more common, potentially leading to better outcomes for patients. Who this helps: Patients with inflammatory bowel disease.

Plain English
This study looked at how satisfied patients with inflammatory bowel disease (IBD) are with their colonoscopy experiences at three hospitals in Italy. Researchers found that 98.8% of the 444 patients were satisfied overall, but those with severe disease activity reported lower satisfaction levels. Increased satisfaction was linked to being treated by expert doctors, being in remission, and having had more colonoscopies in the past two years. Who this helps: This benefits patients with IBD who need regular colonoscopies for monitoring their condition.

Plain English
This study focused on a young man with acute severe ulcerative colitis (ASUC) who did not respond to traditional treatments like steroids and infliximab. After starting a new medication called filgotinib, he showed significant improvement within 48 hours, complete healing of his intestines by week 10, and has remained healthy for one year since treatment. This matters because it highlights a potentially effective option for patients with severe UC who aren’t helped by standard therapies, reducing the need for surgery. Who this helps: This helps patients with acute severe ulcerative colitis who do not respond to existing treatments.

Plain English
This study looked at how self-care practices impact resilience in patients with inflammatory bowel disease (IBD), which includes conditions like Crohn's disease and ulcerative colitis. It involved 401 patients and found that those who managed their self-care better tended to have higher resilience scores, with an average resilience score of 45. Women reported better resilience and self-care monitoring than men. Improving self-care could lead to better health outcomes for IBD patients. Who this helps: This helps patients with inflammatory bowel disease and their healthcare providers.

Plain English
This study focused on improving a medical imaging technique called multispectral optoacoustic tomography (MSOT), which combines light and sound to create detailed images of tissues. Researchers introduced a new method, called phasor analysis, that makes it easier and faster to identify specific signals in these images; this method was able to accurately analyze data 5 times quicker than traditional techniques and helped distinguish between patients with Crohn's disease and healthy individuals. This improvement is important because it enhances the ability of doctors to interpret complex data quickly, making it easier to diagnose and monitor diseases without invasive procedures. Who this helps: Patients with diseases like Crohn's, as well as doctors interpreting their conditions.

Plain English
This study examined how mental health and gut bacteria influence the progression of ulcerative colitis (UC) over five years. It found that UC patients who had failed biological therapies had higher levels of certain harmful gut bacteria and lower levels of beneficial ones, suggesting a connection between gut health and treatment effectiveness. Additionally, patients with severe psychological distress experienced worse outcomes, such as needing surgery or hospitalization. Who this helps: This information can support both patients and doctors in understanding the importance of mental health and gut health in managing ulcerative colitis.

Plain English
This research examined how psychiatric treatments, like antidepressants and other medications, affect patients with inflammatory bowel disease (IBD), which includes conditions like Crohn's disease and ulcerative colitis. The study reviewed 22 studies involving over 45,000 patients and found that antidepressants, especially bupropion, SSRIs, and venlafaxine, often led to better control of IBD symptoms, with improvements noted in disease activity scores for both Crohn's disease and ulcerative colitis. This matters because it suggests that treating mental health issues could help manage gastrointestinal symptoms in IBD patients. Who this helps: Patients with inflammatory bowel disease and their healthcare providers.

Plain English
This study looked at the skills of nurses who care for patients with inflammatory bowel disease (IBD) in Italy. Out of 50 nurses surveyed, they were particularly strong in basic skills, like building relationships with patients (average score of 4.06 out of 5), but showed only moderate skills in more complex areas, such as educating caregivers. Improving training for these nurses is important because better skills can lead to improved care for patients with IBD. Who this helps: Patients with inflammatory bowel disease and their families.

Plain English
This research reviewed how gut bacteria affect the treatment of inflammatory bowel disease (IBD). It found that medications can change the types of bacteria in the gut, and these bacteria can also influence how well the drugs work. The study emphasizes the need for a more personalized approach to treating IBD, as individual responses to treatment vary widely. Who this helps: This helps patients with inflammatory bowel disease by improving their treatment outcomes.

Plain English
This study looked at how inflammation in the gut and changes in gut bacteria affect hearing. Researchers found that mice with inflammation from ulcerative colitis had worse hearing due to increased oxidative stress and inflammation in their ears, while those given gut bacteria from patients whose colitis was in remission had better hearing. This is important because it shows a link between gut health and hearing, suggesting that improving gut bacteria could help protect hearing. Who this helps: Patients with gut conditions that may also be affecting their hearing.

Plain English
This study looked at the emotional and personality traits of patients with two types of inflammatory bowel disease: ulcerative colitis (UC) and Crohn's disease (CD). Researchers found that UC patients showed more anxiety and emotional difficulties, reflected in their scores on certain psychological tests, compared to CD patients. Specifically, UC patients scored higher on issues like hypomania and fears, while CD patients had higher levels of controlled hostility. Understanding these differences is important because it helps tailor psychological support for both groups based on their unique challenges. Who this helps: This helps patients with ulcerative colitis and Crohn's disease by providing insights for better emotional support.

Plain English
This study focuses on the gastrointestinal side effects that patients with advanced kidney cancer face when undergoing combined immunotherapy treatments. The researchers found that problems like diarrhea and colitis are common and can significantly affect patients’ quality of life; these issues often require coordinated care from both cancer and digestive health specialists. Effective management strategies are essential to help patients continue their treatment without serious disruptions. Who this helps: This helps patients undergoing immunotherapy for advanced renal cell carcinoma.

Plain English
This study looked at patients with Crohn's disease (CD) to find out what factors might predict the development of short bowel syndrome (SBS), a serious condition where the intestine is too short to absorb enough nutrients. Out of 232 patients, 18 developed SBS, and two key factors were identified: the longer a person has had Crohn's disease, the higher their risk of developing SBS (increase by 8% for every extra year), and having a specific type of gastrointestinal involvement increased the risk significantly (20 times more likely). Understanding these factors is important because it can help doctors monitor patients more closely and potentially prevent the development of SBS. Who this helps: This helps patients with Crohn's disease and their doctors.

Plain English
This study focused on creating and validating an Italian version of a tool called the General Medication Adherence Scale (GMAS), which is used to measure how well patients follow their medication plans. Researchers tested the new Italian version with 389 patients and found it to be reliable—showing consistent results (with a score of 0.758 for internal consistency) and effectively distinguishing between different levels of adherence. This matters because better assessment of medication adherence can lead to improved treatment for chronic diseases and potentially lower healthcare costs. Who this helps: This benefits patients with chronic conditions and their healthcare providers in Italy.

Plain English
This study examined the resilience of caregivers who support individuals with inflammatory bowel disease (IBD) and looked at how their self-confidence in managing care affects their ability to cope. Researchers found that among 275 caregivers, resilience was generally high, with a median score of 74 out of 100. Self-efficacy, or the caregivers' belief in their ability to help manage the disease, was key in improving their resilience, especially when they actively engaged in managing the patient's care. Who this helps: This research benefits caregivers of IBD patients by providing insights into how to strengthen their coping skills and support systems.

Plain English
This study looked at the risks of blood clots and heart problems in patients with ulcerative colitis who started advanced treatments. Researchers followed 300 patients for about 27 months and found low rates of these events: only four patients experienced issues, including two blood clots and two heart-related problems. This matters because it indicates that patients with ulcerative colitis using advanced therapies generally have low risks of these severe complications, easing concerns about their treatments. Who this helps: This helps patients with ulcerative colitis and their doctors make informed treatment decisions.

Plain English
This study focused on creating and testing an Italian version of a questionnaire to measure patient satisfaction with telemedicine for inflammatory bowel disease (IBD). The research involved 180 IBD patients and found that 80% felt telemedicine improved their disease management, while 87% found technology easy to use. This is important because understanding patient satisfaction can help improve telemedicine services and make them a better option for IBD care. Who this helps: Patients with inflammatory bowel disease.

Plain English
This study focused on how patients with inflammatory bowel diseases (IBDs) feel about their relationships with IBD nurses. It found that 69.7% of patients had excellent relationships with their nurses, which boosted their trust and satisfaction in treatment. Patients who could name their IBD nurse felt more confident in their care, underlining the importance of including dedicated nurses in managing IBD. Who this helps: This helps patients with inflammatory bowel diseases by highlighting the value of having a dedicated nurse in their care team.

Plain English
This study looked at how to improve research on inflammatory bowel disease (IBD) by using new methods that better reflect real-life situations. It found that combining different research techniques, such as personalized models that mimic human gut responses, can lead to better understanding and treatment options. This approach matters because it can improve the effectiveness of therapies, ensuring they are relevant to a wider range of patients and their needs. Who this helps: Patients with inflammatory bowel disease and their healthcare providers.

Plain English
This study looked at how inflammatory bowel diseases (IBD) like Crohn's disease and ulcerative colitis are linked to a higher risk of heart and blood vessel problems, especially in younger people and during flare-ups. It found that people with IBD have a consistent but moderate increase in risks for issues like heart attacks and strokes, with the risk getting higher when inflammation is active. The research highlights the importance of managing IBD carefully because effective treatment can lower heart risks. Who this helps: Patients with inflammatory bowel diseases and their healthcare providers.

Plain English
This study looked at whether a combination of multistrain probiotics and vitamin D could improve gut health in people with irritable bowel syndrome (IBS) who don't have constipation. Researchers found that after 12 weeks, participants who took the probiotics and vitamin D had a notable decrease in a marker indicating gut permeability (zonulin) and better stool consistency compared to those who took a placebo. Specifically, they experienced a 19.5 ng/mL reduction in zonulin levels and improvements in stool quality and frequency. Who this helps: This helps patients with irritable bowel syndrome, particularly those without constipation.

Plain English
This study examined the effectiveness and safety of the drug filgotinib for treating ulcerative colitis (UC) in patients who had already tried other treatments. Out of 102 patients followed for about six months, 46% achieved clinical remission by the end of the study, and those who started filgotinib first had a higher success rate compared to those on second or third lines of therapy. This research is important as it shows that using filgotinib early in treatment can lead to better outcomes with relatively few adverse effects. Who this helps: This benefits patients with ulcerative colitis, particularly those looking for effective treatment options.

Plain English
This study looked at how using ultrasound during surgery for Crohn's disease could help surgeons remove affected parts of the small intestine more effectively. Researchers found that using this method led to a significant reduction in the rate of positive margins—where cancer cells are found at the edges of the surgically removed tissue—going from 48.1% in the traditional approach to 18.5% with ultrasound use. This matters because reducing positive margins can decrease the chances of the disease returning after surgery. Who this helps: This aids patients with Crohn's disease by improving surgical outcomes.

Plain English
This study looked at the effectiveness and safety of Upadacitinib (UPA) in treating patients with ulcerative colitis who did not respond to other treatments. Among 202 patients, 45.5% achieved clinical remission at 8 weeks, and by the end of the study, 60.2% were in remission, with 84.6% showing healing in their intestinal lining. The research confirms that UPA is a valuable option for patients with difficult-to-treat ulcerative colitis, with a low rate of serious side effects. Who this helps: Patients with ulcerative colitis who have not had success with other treatments.

Plain English
This study looked at the effectiveness and safety of two drugs, tofacitinib and vedolizumab, for treating ulcerative colitis in patients who didn't respond to another type of medication. Researchers found that by week 26, both drugs were equally effective, with about 38% of patients reaching clinical remission. However, tofacitinib helped patients feel better faster at week 8 but had a higher chance of patients stopping the treatment. Who this helps: This benefits patients with ulcerative colitis who are not responding to anti-TNF medications.

Plain English
This study looked at how using e-cigarettes and heat-not-burn tobacco affects the chances of Crohn's disease coming back after surgery. It involved nearly 1,000 patients and found that those who smoked traditional cigarettes had a recurrence rate of 69.4%, HNBT users had a rate of 60.6%, and e-cigarette users had a rate of 63.9%, all of which are higher than the 40.8% rate among non-smokers. This is important because it shows that these smoking habits increase the risk of Crohn's disease returning, which can affect treatment decisions and health outcomes for patients. Who this helps: Patients with Crohn's disease and their healthcare providers.

Plain English
This study examined how resilience, or the ability to cope with stress, affects depression and anxiety in patients with inflammatory bowel diseases (IBD) like Crohn's disease and ulcerative colitis. Researchers found that patients with higher resilience reported fewer symptoms of depression and anxiety; for example, in Crohn's patients, those with high resilience experienced 72.6% fewer depressive symptoms and 66.8% fewer anxiety symptoms. This matters because it highlights the importance of building resilience as a way to improve mental health in IBD patients, especially when their disease is more active. Who this helps: This helps patients with inflammatory bowel diseases and their healthcare providers.

Plain English
This study looked at the effectiveness and safety of the drug vedolizumab for patients with inflammatory bowel disease (IBD) over two years. Researchers found that about 31.6% of patients with Crohn’s disease and 39.7% with ulcerative colitis experienced clinical remission, and there were very few adverse events, averaging 0.14 per patient per year. Understanding who is more likely to benefit from this treatment helps improve patient care. Who this helps: This helps patients with inflammatory bowel disease and their doctors.

Plain English
This research examines how inflammatory bowel disease (IBD) leads to muscle loss, known as sarcopenia. It found that chronic inflammation and changes in gut bacteria and nutrition disrupt muscle health, with specific biological mechanisms identified, such as the activation of certain pathways that promote muscle breakdown. Understanding these processes could lead to better ways to treat or prevent muscle loss in IBD patients, which is crucial since losing muscle can significantly impact their overall health. Who this helps: This helps patients with inflammatory bowel disease.

Plain English
This study looks at a new way of using artificial intelligence called federated learning to improve research on inflammatory bowel diseases while keeping patient data private. Researchers found that federated learning can match or even outperform traditional data handling methods in diagnosing and predicting health outcomes, with performance scores over 0.80 in many cases. This approach is important because it allows different medical institutions to collaborate on creating better predictive models without needing to share sensitive patient information. Who this helps: This helps patients with inflammatory bowel diseases by improving diagnostic tools and treatment predictions.

Plain English
This study looked at a 30-year-old pregnant woman suffering from severe ulcerative colitis, a condition that can be life-threatening and typically requires urgent medical treatment. After trying several other treatments without success, she received Mirikizumab, which led to significant improvement in her condition within just one day, and she kept doing well for the rest of her pregnancy. This matters because it shows that Mirikizumab can be a potentially effective treatment option for severe ulcerative colitis in pregnant women, where limited options exist. Who this helps: Patients with severe ulcerative colitis, especially those who are pregnant.